Samsara BioCapital — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor.
BiotechHealthtechNewton, US
John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Ryan Berry(Director)Donald McCarthy(Director)John Edwards(Director)Yajun Xu(Director)
Board seatMichael Dybbs· per SEC Form D
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)Sanford Madigan(Co-Founder, President & Chief Business Officer)Analeah Heidt(Chief Scientific Officer)
Board seatMarcos Milla· per SEC Form D
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Peter Bach(Executive Officer)Elizabeth Homans(Director)Justin Kao(Director)Jennifer Buechel(Executive Officer)Victor Velculescu(Executive Officer, Director, Promoter)Douglas Schenkel(Executive Officer)
Board seatMichael Dybbs· per SEC Form D
BiotechSeattle, US
Erik Anderson(Director)Mark Litton(Director)Robert Carlson(Director)Craig Behnke(Executive Officer)Ed Schlect(Director)John Morrow(Executive Officer)
Board seatMarcos Milla· per SEC Form D · $23M raise · filed Apr 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.